Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647758 | 0.88 | MAPT (0.39) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL20647812 | 0.83 | CYP3A4 (0.34) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL20647810 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL16903077 | 0.80 | MAPT (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL22818589 | 0.79 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL20647780 | 0.79 | MAPT (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL20647679 | 0.78 | ALDH1A1 (0.40) | CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL20647787 | 0.77 | CYP3A4 (0.40) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL19841949 | 0.77 | MAPT (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL20647809 | 0.76 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | CYP3A4 273/4885CYP2D6 1425/4885CYP2C9 979/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | CYP3A4 273/4885CYP2D6 1425/4885CYP2C9 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.